An article by Thai business platform ลงทุนแมน, recently shared by the Thai-Swedish Chamber of Commerce, sheds light on what ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major competitor in China.

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to ...

In a surprising move, Novo Nordisk joined forces in April with Dudum’s telehealth company, Hims & Hers, in a bid to expand sales of Wegovy to the growing pool of online patients.

SourceL Finviz Novo Drama Hims & Hers Health slumped last week as Novo Nordisk ended the partnership with the online health and wellness platform to sell Wegovy, despite just forming a partnership.

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking approval for a new and higher dose of its popular obesity medication ...

Novo Nordisk A/S (NYSE:NVO) is one of the 10 best defensive stocks to buy in a volatile market. On July 7, the company received a significant boost in its proposed $2.34 billion investment in a ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.